Atjaunināt sīkdatņu piekrišanu

E-grāmata: Recent Advances and Challenges in the Treatment of Major Depressive Disorder

Edited by
Citas grāmatas par šo tēmu:
  • Formāts - PDF+DRM
  • Cena: 237,93 €*
  • * ši ir gala cena, t.i., netiek piemērotas nekādas papildus atlaides
  • Ielikt grozā
  • Pievienot vēlmju sarakstam
  • Šī e-grāmata paredzēta tikai personīgai lietošanai. E-grāmatas nav iespējams atgriezt un nauda par iegādātajām e-grāmatām netiek atmaksāta.
Citas grāmatas par šo tēmu:

DRM restrictions

  • Kopēšana (kopēt/ievietot):

    nav atļauts

  • Drukāšana:

    nav atļauts

  • Lietošana:

    Digitālo tiesību pārvaldība (Digital Rights Management (DRM))
    Izdevējs ir piegādājis šo grāmatu šifrētā veidā, kas nozīmē, ka jums ir jāinstalē bezmaksas programmatūra, lai to atbloķētu un lasītu. Lai lasītu šo e-grāmatu, jums ir jāizveido Adobe ID. Vairāk informācijas šeit. E-grāmatu var lasīt un lejupielādēt līdz 6 ierīcēm (vienam lietotājam ar vienu un to pašu Adobe ID).

    Nepieciešamā programmatūra
    Lai lasītu šo e-grāmatu mobilajā ierīcē (tālrunī vai planšetdatorā), jums būs jāinstalē šī bezmaksas lietotne: PocketBook Reader (iOS / Android)

    Lai lejupielādētu un lasītu šo e-grāmatu datorā vai Mac datorā, jums ir nepieciešamid Adobe Digital Editions (šī ir bezmaksas lietotne, kas īpaši izstrādāta e-grāmatām. Tā nav tas pats, kas Adobe Reader, kas, iespējams, jau ir jūsu datorā.)

    Jūs nevarat lasīt šo e-grāmatu, izmantojot Amazon Kindle.

This book reviews all aspects of major depressive disorder (MDD), casting light on its neurobiological underpinnings and describing the most recent advances in management. The book is divided into four sections, the first of which discusses MDD from a network science perspective, highlighting the alterations in functional and structural connectivity and presenting insights achieved through resting state functional MRI and the development of neuroimaging-based biomarkers. The second section examines important diagnostic and neurobiological issues, while the third considers the currently available specific treatments for MDD, including biofeedback, neurofeedback, cognitive behavioral therapy, acceptance and commitment therapy, neuromodulation therapy, psychodynamic therapy, and complementary and alternative medicine. A concluding section is devoted to promising emerging treatments, from novel psychopharmacological therapies through to virtual reality treatment, immunotherapy, biomarker-guided tailored therapy, and more. Written by leading experts from across the world, the book will be an excellent source of information for both researchers and practitioners.

Part I. Molecular Biology-based Treatment for Depression.
Chapter
1.
 Neuroendocrinological Treatment Targets for Depressive Disorder.
Chapter
2.
Psychophamacological Approaches for Neural Plasticity and Neurogenesis in
Major Depressive Disorder.
Chapter
3. Efficacy, Safety and Tolerability of
Psychedelics in Treatment Resistant Depression (TRD).
Chapter
4. Probiotics
and Fecal Microbiota Transplantation in Major Depression: Doxa or Episteme?.-
Chapter
5. Induced Pluripotent Stem Cells (iPSC) Technology for Major
Depression.
Chapter
6. Combining Complementary and Alternative Medicine
(CAM) with Conventional Treatments for Major Depressive Disorder.- Part II.
Brain Network-based Treatments for Depression.
Chapter 7.  Application of
Transcranial Direct and Alternating Current Stimulation (tDCS & tACS) on
Major Depressive Disorder.
Chapter 8.  Repetitive Transcranial Magnetic
Stimulation (rTMS) in Major Depression.
Chapter
9. Deep Brain Stimulation
(DBS) in Treatment-resistant Depression (TRD): Hope and Concern.
Chapter
10.
Electroconvulsive Therapy (ECT) in Major Depression: Oldie but Goodie.- Part
III. Psychological Intervention based Treatments for Depression.
Chapter
11.
Cognitive Behavioral Therapy and Mindfulness-based Cognitive Therapy for
Depressive Disorders: Enhancing Access and Tailoring Interventions in Diverse
Settings.
Chapter
12. Acceptance and Commitment Therapy for Major Depressive
Disorder: Navigating Depression Treatment in Traditional and Digital Settings
with Insights from Current Research.
Chapter
13.  The Importance of
Psychotherapy for Treatment Resistant Depression.
Chapter
14. Personalized
Well-Being Therapy (WBT) for Major Depression.- Part IV. Digital Psychiatry
based Treatments for Depression.
Chapter
15. The Potential and Challenges of
Virtual Reality as an Adjunctive Treatment of Depression Patients.
Chapter
16. The New Emerging Treatment Choice for Major Depressive Disorders: Digital
Therapeutics.
Chapter
17. Telepsychiatry in the Treatment of Major
Depressive Disorders.- Part V. Personalized Precision Treatments for
Depression.
Chapter
18. Precision Medicine in Depression: The Role of
Proteomics and Metabolomics in Personalized Treatment Approaches.
Chapter
19. Biomarker Guided Tailored Therapy in Major Depression.
Chapter
20.
 Navigating the Intersection of Technology and Depression Precision Medicine.
Dr. Yong-Ku Kim is a professor of Psychiatry at College of Medicine, Korea University. He received a MD degree from College of Medicine, Korea University in 1987 and a PhD in psychiatry from Korea University in 1998. Dr. Kim has been affiliated with Korea University since 1998, first as an assistant professor (19982000), then as associated professor (20012005), and professor (2006present). For the past 30 years, his professional activities have extended beyond the area of pure clinical or research work. Dr. Kim has well over 500 publications in peer-reviewed international journals, and 20 publications of book and have made over 100 academic presentations in his area of interest. Dr. Kim is a fellow of Collogicum Internationale Neuropsychopharmacologicum, International Society for Affective Disorders, World Federation of the Society of biological Psychiatry. He currently sits on the editorial boards of some leading academic journals in the field of neurobiology. His work has been recognized by several prestigious awards, including Astrageneca Award, Research Award from Korean Society of Neuropsychiatry, and Dr. Paul Janssen Schizophrenia Research Award. Dr. Kim is the past president of Korean Society of Biological Psychiatry (20162018) and the chairman of Korean Neuropsychiatric Association (2023-present).